Topiramate in add-on therapy: Results from an open-label, observational study  by Krakow, K. et al.
Seizure (2007) 16, 593—600
www.elsevier.com/locate/yseizTopiramate in add-on therapy: Results from
an open-label, observational study
K. Krakow a, U. Lengler a, K. Rettig b, A. Schreiner c, B. Schauble d,*
on behalf of the TOP-GER-3 investigators
aDepartment of Neurology, J.W. Goethe-University, Schleusenweg 26, 60528 Frankfurt, Germany
bG.E.M., Meerbuscher Strasse 47, 40670 Meerbusch, Germany
cDepartment of Medical Affairs, Janssen-Cilag EMEA, Raiffeisenstrass 8, 41470 Neuss, Germany
dDepartment of Medical and Scientific Affairs, Janssen-Cilag Neuss, Raiffeisenstrasse 8,
41470 Neuss, Germany
Received 28 November 2006; received in revised form 10 April 2007; accepted 26 April 2007
KEYWORDS
Topiramate;
Anticonvulsive drugs;
Broad spectrum
anticonvulsant;
Epilepsy;
Add-on therapy
Summary An open-label, observational prospective study assessed the effective-
ness of topiramate (TPM) as add-on therapy. A total of 450 patients aged 12 and above
with a diagnosis of epilepsy and at least one epileptic seizure during the 12-week
retrospective baseline were to be documented. After baseline evaluation, topiramate
was added. Ninety-five percent of patients had at least one baseline AED, most
commonly Carbamazepine (53%) or Valproate (34%). In 5% TPM was started in
monotherapy. Topiramate dose titration and target dose was determined by clinical
response and side effect profile. Patients were intended to be followed for a total of 1
year which included 6 visits during which seizure frequency, adverse events, weight as
well as clinical global impression were recorded. During the 12 weeks retrospective
baseline, a median of 2.8 seizures per month were recorded which reduced sig-
nificantly to 0.7 per month during the complete treatment phase ( p < 0.0001).
Seventy-two percent of patients had a 50% seizure reduction. Ten percent of
patients were seizure free during the study. The most commonly reported adverse
events were difficulties withmemory (4.2%), somnolence (3.6%), and dizziness (2.7%).
Overall, topiramate was well tolerated, and only 5% of patients discontinued treat-
ment due to an adverse event. Retention in the study was higher than previously
reported during randomized, dose controlled studies and is likely due to individua-
lized doses as well as slower titration used.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +49 2137 955 398;
fax: +49 2137 955 486.
E-mail address: bschaeu2@jacde.jnj.com (B. Schauble).
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Less than 50% of patients become seizure-free with
thefirstanticonvulsantdrug 1,2 and failuredue to lack
of efficacy is associated with poor outcome for the. Published by Elsevier Ltd. All rights reserved.
594 K. Krakow et al.individual. Excessmortality, cognitive andbehavioral
dysfunction as well as social and educational disad-
vantages are negative consequences of uncontrolled
epilepsy.3 A second monotherapy or a combination
therapy is frequently unavoidable and an anticonvul-
sant with few drug—drug interactions is generally
preferred. Topiramate (TPM) is a sulfamate-substi-
tuted monosaccharide, with multiple mechanisms of
action that includeblockadeof voltage-sensitive sod-
iumchannels,potentiationofGABAA-evokedchloride
flux, blockade of kainate/AMPA type of glutamate
receptors, and reduction of type L-calcium channels
activity.4,5 Various seizure types can be treated
effectively. The lack of significant pharmacokinetic
interactions, minimal protein binding as well as the
long half-life is advantageous in clinical settings.6
In early randomized, placebo-controlled trials,
topiramatewasshowntobehighlyefficaciousdemon-
strating a significant median reduction in seizure
frequency at doses of 200—600 mg/day 7 and seizure
freedom in 5% of drug-resistant patients. However,
tolerability of the drug was reduced because fixed
titration and target doses aswell as inability to adjust
concomitant AEDs. As a result of this, treatment
during drug trials is frequently discontinued due to
adverse events. In general, 75% of patients dropping
out of from randomized trials will do that within the
first 2 months, often during forced titration without
reduction of concomitant therapy.7,8 Therefore,
results of these trials are only partially applicable
for daily routine, since ease of titration, pharmaco-
kinetic and pharmacodynamic interactions and the
patient’s individual response to seizure control and
medication side effects are important constituents of
individualized therapy. Studies reflecting the daily
use of topiramate in adult patients with difficult to
treat epilepsy add valuable information regarding
overall effectiveness of the drug.
In order to assess this further, we conducted a 1-
year prospective open-label multicenter study to
assess topiramate in add-on therapy in patients with
epilepsy who should be diagnosed within the last 3
years and who failed several AEDs due to insufficient
efficacy and/or tolerability under the conditions of
daily clinical practice. Doses of TPM were deter-
mined by the treating physician according to pre-
scribing information based on tolerability and
seizure reduction.Methods
Study design and patients
Patients were to be enrolled in this prospective,
open-label multicenter study provided they were atleast 12 years of age, had a confirmed diagnosis of
epilepsy according to the ILAE 1989 classification,9
the diagnosis was made within the last 3 years and
they were drug-naı¨ve to TPM. In addition, a mini-
mum of one epileptic seizure during the 12-week
retrospective baseline was required. Patients were
to be followed up for 1 year at 158 study centers in
Germany.
Treatment
Target doses and dose escalation of topiramate add-
on therapy were based upon the physicians’ discre-
tion. However, a starting dose of 25 mg/day with a
weekly escalation of 25 mg/day thereafter given
b.i.d. was recommended according to the German
TPM prescribing information. No upper or lower dose
limit was set. Concomitant AEDs could be adjusted
upon the physicians’ discretion.
Assessments and documentation
On the initial visit, demographic data, a thorough
medical and epilepsy history was documented and a
comprehensive physical and neurological examina-
tion was conducted. Further visits at 1, 2, 3, 6, 9, and
12 months were documented. During each visit, sei-
zure diaries were reviewed and number and type of
seizures were recorded. In addition, adverse events
including seriousness, causality with TPM treatment,
and outcome were noted. AEDs and other concomi-
tant medications, medical and neurological findings
were documented. At the final visit the patients and
physicians were asked to assess the efficacy of the
treatment using a 5-point rating scale (very good,
good, reasonable, unchanged, worsened) and the
tolerability using a 4-point rating scale (very good,
good, moderate, poor).
Analysis and statistics
Safety data were analyzed for the entire study
period in all subjects who had received topiramate
at least once. In the intent-to-treat population for
effectiveness all patients who received TPM at least
once and with at least one post-baseline observation
were included. The maintenance phase was deter-
mined for each single patient: it was defined as the
period starting from the individual study end back-
wards where a stable dose of TPM within the range
of50 mg was applied over at least 12 weeks. Thus,
patients in whom the study was prematurely termi-
nated before 12 weeks or in whom the dose was
changed for more than 50 mg/day during the last 12
week-observation period do not have amaintenance
phase.
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Table 1a Patient demographics and disease descrip-
tion (n = 450)
Parameter Value
Demographic characteristics
Gender, male/female, n (%) 232 (52)/218 (48)
Mean age, years (S.D.) 40.3 (S.D. 16.7)
Age range, years (3 patients
<12 years)
10—93
At least one concomitant
disease, n (%)
153 (34)
At least one concomitant
medication, n (%)
124 (28)
AED started during the
observation (other
than TPM), n (%)
55 (12)
Epilepsy characteristics
Duration of epilepsy, months
Mean (S.D.) 87.8 (128.4)
Median (range) 30.9 (0.2—848.5)
Patients with duration of
epilepsy 3 years, n (%)
272 (60)
Patients with duration of
epilepsy >3 years, n (%)
173 (39)The 4-week seizure frequency during treatment
was determined per patient based on the seizures
cumulatively counted over the whole treatment
period and the maintenance phase if applicable,
respectively. Mean  standard deviation (S.D.) and
median values were calculated and the change
versus baseline was assessed, using the Wilcoxon
signed-rank test, two sided at the 5% significance
level. Responder rates were defined as the propor-
tion of patients achieving 50- (primary endpoint),
75- and 100% reduction in mean monthly seizure
frequency from study entry to endpoint compared to
the 12-weeks retrospective baseline. Change in
body weight was assessed at each visit and the
finally observed weight compared to baseline using
the Wilcoxon signed-rank test, two-sided at the 5%
significance level. For comparisons between sub-
groups the two-sided Mann—Whitney U test or the
Chi square test was used depending on the scale
level. All inferential tests were performed without
adjustment of the significance level for multiple
testing.Patients with no information
on duration of epilepsy
n (%)
5 (1)
Ethiology, n (%)
Idiopathic, n (%) 176 (39)
Cryptogen, n (%) 66 (15)
Symptomatic, n (%) 204 (45)
Thereof (multiple answers possible)
Vascular, n (%) 50 (11)
Tumor, n (%) 34 (8)
Others, n (%) 128 (28)
Unknown 4 (1)
Seizure classification, n (%)
Focal 262 (58)
Generalized 156 (35)
Other 14 (3)
Unclear 18 (4)
Number of AEDs at start of observation
0 AED, n (%) 21 (5)
1 AED, n (%) 297 (66)
2 AEDs, n (%) 127 (28)
3 AEDs, n (%) 5 (1)Results
Patient characteristics
Documentation was available for a total of 454
patients; 4 of these never received topiramate
therapy and were excluded from all analyses,
which are based on 450 patients. These 450
patients were followed up for a median time of
364 days. In 60 patients, topiramate therapy was
prematurely discontinued due to various reasons
which were noted by the investigator on the case
record form.
In several patients the selection criteria were not
fulfilled (multiple violations possible): three
patients were younger than 12 years, 21 patients
had no AED at start of observation, 173 patients had
a history of epilepsy of more than 3 years. Naturally,
these patients were all included into both the
safety- and ITT analyses.
Out of 450 safety and intention-to-treat-
patients, 232 (52%) were male, mean age was
40.3 years in a range of 10—93 years (Table 1).
One hundred and seventy-six patients (39%) were
classified as having idiopathic epilepsy, 66 (15%) had
cryptogenic epilepsy and the remainder had symp-
tomatic epilepsy except for four patients (1%) in
whom the epilepsy was not classified. Most com-
monly listed underlying etiologies were vascular
causes, infections and dysplasias. In 128 patients,
the neurological examination was abnormal (often
due to a preexisting hemiparesis) and 34% had con-comitant diseases, most frequently listed were
hypertension and diabetes.
Ninety-five percent of patients had at least one
baseline AED, most commonly Carbamazepine (53%)
or Valproate (34%). In 5%, TPM was started in mono-
therapy. Other concomitant medications were listed
in 27.5% patients and included psychotropics, anti-
diabetic medication, antihypertensives and platelet
inhibitors.
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Table 2 Topiramate maintenance doses
Maintenance dose (mg/day) Number of patients (%)
25—50 16 (4)
51—100 64 (15)
101—200 165 (39)
201—300 94 (22)
301—400 56 (13)
>400 26 (6)
In 421 patients with a maintenance phase of at least 12 weeks.
Table 1b Anticonvulsive therapy at study start
Type of AED Number of patientsa (%)
Carbamazepine 240 (53)
Valproate 152 (34)
Phenytoin 40 (9)
Lamotrigine 37 (8)
Oxcarbazepine 27 (6)
Gabapentin 17 (4)
Primidone 13 (3)
Other 38 (8)
No AED treatment 21 (5)
a Multiple AEDs possible.Topiramate dose
In the ITT-sample, patients took on average 235mg/
day (median 200 mg/day) topiramate at the end of
the study with a wide range of 25—1200 mg/day.
Approximately 94% of all patients (n = 421) reached
a maintenance phase which was defined as a stable
dose of topiramate within the range of 50 mg over
at least 12 weeks. About 75% of these patients were
treated with maintenance doses between 100 and
400 mg/day (Table 2). The mean dose during theTable 3a Seizure frequency before and during treatment
Seizure frequency
per 4 weeks
A
12-weeks retrospective baseline Mean  S.D. 1
Median (range) 2
Treatment period C
Mean  S.D. 4
Median (range) 0
Pre—post change Mean  S.D. 
95%-CI (mean) (
Median (range) 
Pre—post change % Mean  S.D. 
95%-CI (mean) (
Median (range) 
Wilcoxon pre—post p <
CI, confidence interval.maintenance phase was 237 mg/day (median
200 mg/day) with a wide range of 25—800 mg/day.
Seizure response rate
Seizure frequency and response rates were analyzed
in 450 patients for the ITT population and separately
for the 421 patients with a 12-week maintenance
phase (see Table 3). In the latter group, the mean
seizure frequency was 11.4  39.4 per month during
the 12-week retrospective baseline (median 3,
range: 0.3—463; Table 3a). During the TPM main-
tenance phase, median monthly seizure frequency
reduced significantly to 0.4 seizures (range 0—246;
p < 0.0001 versus baseline). Seventy-six (18%)
patients were seizure free during the maintenance
phase which lasted at least 3 months with a median
duration of about 10 months (see Table 3b).
As already mentioned, patients were to have had
epilepsy for less than 3 years in this study. Actually,
however, 173 (38.4%) patients with a history of
epilepsy of more than 3 years were included by
the physicians. Since the patient population thus
falls somewhere between ‘‘recent onset’’ epilepsy
and the very refractory patients typically enrolled in
blinded trials, a post hoc subgroup-analysis was
performed contrasting patients with an epilepsy
history of 36 versus patients with an epilepsy
history of >36 months. The results of this sub-
group-analysis can be summarized as follows:
In both subgroups a significant reduction in seizure
frequency (retrospective baseline versus seizure fre-
quency during the whole observation period) was
observed (Wilcoxon-tests: p < 0.0001). Mean seizure
frequency during the retrospective baseline was
smaller in the ‘36months’-group (8.50  27.64 sei-of topiramate
ll patients n = 450 Patients with a
maintenance phase of at
least 12 weeks (n = 421)
1.3  39.3 11.4  39.4
.8 (0.3—462.7) 3.0 (0.3—462.7)
omplete treatment phase Maintenance phase
.3  18.5 2.9  15.0
.7 (0—258.7) 0.4 (0—245.7)
7.0  28.7 8.2  31.4
9.65, 4.35) (11.20, 5.20)
1.6 (331—32.8) 1.9 (362—35.8)
53.8  117.6 67.6  119.0
64.67, 42.93) (78.97, 56.23)
73.7 (100—1672.7) 86.5 (100—1672.7)
0.0001 <0.0001
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Table 3b Seizure response rates comparing retrospective baseline with complete observation period and main-
tenance phase, respectively
Seizure response rates (%) All patients n = 450 Patients with a maintenance phase
of at least 12 weeks (n = 421)
Complete treatment phase Maintenance phase
50 323 (72%) 350 (83%)
75 217 (48%) 274 (65%)
100 46 (10%) 76 (18%)seizures/4 weeks) than in the ‘>36 months’-group
(15.98  52.78 seizures/4 weeks); the differences
was, however, not significant (Mann—WhitneyU test:
p = 0.098). Mean pre-post- reduction of seizure fre-
quency between retrospective baseline and the
whole observation period was 4.69  15.64 sei-
seizures/4 weeks in the 36 months’-and 10.75 
41.76 seizures/4weeks in the ‘>36months’-group (U
test: p = 0.951).
There was a significant difference (Chi square
test: p = 0.011) between the distributions of the
classified relative pre—post changes: derived from
these distributions we found a 50% response-rate
of 77.21% in the ‘36 months’- and of 63.58% in the
‘>36 months’-group.
In 82% of the 450 cases efficacy of treatment was
judged by the physician as very good or good, in 12%
as reasonable, unchanged or worsened, and in 6% no
assessment was available. The corresponding per-
centages for the patients’ assessments were 78, 14
and 8%, respectively.
Tolerability and safety
Tolerability data from all 450 patients exposed to
TPM were analyzed. In 64 patients (14.2%) a totalTable 4 Most frequent adverse events and main reasons f
Number of patients (% of 450) with adverse events
At least one adverse event
At least one adverse event with causal relationship
Memory difficulties
Somnolence
Dizziness
Weight decrease
Depressive symptoms
Nausea
Gastrointestinal problems
Paresthesia
Speech disturbances
Skin problems
a Multiple reasons possible.number of 181 treatment-emergent adverse events
(TEAE) were documented. The most common TEAEs
were difficulties with memory (n = 19; 4.2%), som-
nolence (n = 16; 3.6%), and dizziness (n = 12; 2.7%).
Details of the adverse events are provided in
Table 4. In 23 patients (5.1%) TPM was discontinued
due to an adverse event, in 11 patients (2.4%) due to
insufficient efficacy, and in 26 patients due to other
reasons, mainly loss of follow-up. Adverse events
leading to discontinuation of TPM encompassed
cognitive adverse events including speech distur-
bance in five patients (1.1%). Overall, 12 serious
adverse events occurred in five patients; these are
listed in Table 4.
Although not very common under topiramate
therapy, one patient developed skin problems:
while on 25 mg/day topiramate treatment for 8
days, this individual developed vesicles at elbows
and chest which ceased after 12 days treatment
with chamomile cre`me; 4 days later, he developed
efflorescenses at the lower leg and after other 19
days the topiramate therapy was stopped. The cau-
sal relationship was assessed by the investigator as
possible and later as probable, respectively.
Twelve serious adverse events in five patients
were reported. Four serious adverse events occur-or withdrawal
Patients (%) Reason for dropout [number of
patients (% based on patients
with adverse events)] a
64 (14.2) 23 (36)
52 (11.6) 19 (30)
19 (4.2) 4 (6)
16 (3.6) 2 (3)
12 (2.7) 4 (6)
9 (2.0) 5 (8)
9 (2.0) 2 (3)
8 (1.8) 1 (2)
8 (1.8) 1 (2)
6 (1.3) 2 (4)
6 (1.3) 1 (2)
1 (1.6) 1 (2)
598 K. Krakow et al.ring in the same patient were thought to be causally
related to topiramate treatment. Listed were
depression (twice), strong weight loss and percep-
tual disorder. Serious adverse events without a cau-
sal relationship to Topiramate were: recurrence of
brain tumor leading ultimately to death, depression
in the context of borderline personality disorder,
cold, forced hospitalization by patient by ingestion
of high doses of topiramate, hypercalcemia, sei-
zures, drowsiness, alcohol delirium.
Body weight
Body weight was documented in 411 patients
(91.3%) both at first and last visit. The mean body
weight at baseline was 73.4  14.5 kg with mean
height of 170.9  9.0 cm. At endpoint, the mean
body weight decreased to 71.8  13.60 kg, which
represents a significant weight loss of 1.6  4.7 kg
( p < 0.0001). A total of 210 patients (51.1%) experi-
enced a weight decrease. However, only in 9
patients (2%) weight decrease was reported as an
adverse event.Global tolerability assessment
At the end of the observation, the treating physician
as well as the patient rated the tolerability of
topiramate on a 4-point rating scale. Physicians
rated the tolerability of TPM as ‘good’ or ‘very good’
in 88% of patients which was comparable to 82% of
patients who rated the tolerability of TPM as ‘very
good’ or ‘good’. Eighty-five percent of patients
completed an observation period of at least 48
weeks.Discussion
The main aim of this study was to explore effec-
tiveness of TPM as add-on therapy in patients seen in
neurology and epilepsy private practices. The addi-
tion of TPM to a regimen of 1—2 concomitant antic-
onvulsants resulted in a 50% seizure reduction in
72% of patients during the complete treatment
phase. In addition, 10% achieved seizure-freedom
during the treatment phase and 18% during the
maintenance phase which was defined to last for
at least 12 weeks without change of TPM dose for
more than 50 mg/day. This response rate is substan-
tially higher than reported during the placebo-con-
trolled, fixed-dose regulatory trials.7 In Reife’s
meta-analysis a 50% seizure reduction occurred
in 24—44% of patients taking doses between 200
and 600 mg/day of topiramate. Responder rates inour study are higher which is likely due to the fact
that less severe patients were documented in this
study. This is confirmed by the additional subana-
lyses differentiating between recent onset epilepsy
(36 months) and longer duration epilepsy showing
that the 50% responder rate is higher in the first
group though mean seizure reduction are not dif-
ferent between the two groups.
Comparisons with other add-on therapy trials
published recently are hampered by differences in
patient selection, trial design and types of epilepsy
studied. In Guberman’s study,10 which was a pla-
cebo-controlled double-blind study, median percent
reduction in seizure frequency from baseline to
endpoint was 44% with topiramate which contrasts
to 74% in our study and 20% in the placebo arm.
There, a significant therapeutic effect was seen at 2
weeks with a dose of 100 mg/day of topiramate
despite patients were on an enzyme inducing con-
comitant AED (Carbamazepine). The median seizure
frequency/month was 7 contrasting to our patient
population (baseline median seizure frequency was
2.8), however, supporting that even with lower
doses of topiramate a clinically relevant seizure
reduction can be achieved. Our study supports this
finding furthermore since the median dose of topir-
amate found to be clinically useful and tolerated
was 200 mg/day.
The patient retention rate in the present study
was 85% with only 5.1% terminating the observation
early due to an adverse event. The number of with-
drawals due to adverse events is lower than fre-
quencies from randomized controlled trials which
range between 7 and 16%.11 Individualized dosing as
well as dose adjustments when needed may have
contributed to the low drop-out rate. Adverse
events reported during this study were the ones
known occurring with TPM therapy. Reports of dizzi-
ness, difficulties with memory or somnolence were
rare and occurred considerably less frequently than
reported before. Somnolence for instance was
reported considerably less often (3.6%) than in
Reife´s pooled analysis (30%) which at least in part
can be attributed to a lower starting dose and slower
titration rate compared to early controlled TPM
studies.11
The results of this study suggest that topiramate
100—200 mg/day is an appropriate initial target
dose for add-on therapy. In most of the patients
in this study, TPM was added to an enzyme inducing
antiepileptic drug (Carbamazepine in 53% of
patients). This indicates that even lower doses
might be considered when TPM is used in patients
without an enzyme-inducing co-medication.
In conclusion, in an open naturalistic setting
topiramate used in low dose and individualized
Topiramate in add-on therapy 599titration was effective and well tolerated in add-on
therapy. In line with controlled studies, good seizure
response rates, high patient retention and good
tolerability were observed. The results of this study
is supported by findings of a recent controlled study
10 which showed that 100—200 mg/day is an appro-
priate initial target dose in the add-on therapy for
treatment-resistant epilepsy.Acknowledgements
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